ストックスクリーナーアプリを入手
1.52
2.70%
0.04
Coherus Biosciences Inc (CHRS) 最新ニュース
There's No Escaping Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Muted Revenues Despite A 38% Share Price Rise - Simply Wall St
Coherus to Present Final Phase 2 Casdozokitug Combination - GlobeNewswire
Coherus BioSciences to Present Groundbreaking Cancer Treatment Data at ASCO-GI 2025 - StockTitan
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development - Seeking Alpha
Short Interest in Coherus BioSciences, Inc. (NASDAQ:CHRS) Drops By 7.0% - MarketBeat
Coherus Biosciences' SWOT analysis: stock faces headwinds amid transition - Investing.com
Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Sold by Jacobs Levy Equity Management Inc. - MarketBeat
Coherus BioSciences to divest UDENYCA franchise for up to $558.4M - MSN
Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Sold by Disciplined Growth Investors Inc. MN - MarketBeat
California-Based Biotech Rallies Strongly Following $558.4M Divestiture - MSN
Coherus price target raised at Baird on agreement to sell Udenyca - Investing.com Canada
Coherus BioSciences director Tzoumakas to exit board By Investing.com - Investing.com Canada
Coherus BioSciences director Tzoumakas to exit board - Investing.com
Intas acquires Udenyca from Coherus BioSciences in potential $558 million deal - BioProcess Insider
Coherus BioSciences (FRA:8C5) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com
CHRS (Coherus BioSciences) Price-to-Operating-Cash-Flow : (As of Dec. 05, 2024) - GuruFocus.com
Coherus Biosciences Announces Board Member Resignation - TipRanks
Coherus Biosciences' SWOT analysis: stock faces headwinds amid transition By Investing.com - Investing.com Australia
Latham Watkins Advises Coherus in Divesture of UDENYCA Franchise to Intas Pharmaceuticals - Latham & Watkins LLP
Accord acquires Coherus’ Udenyca business - The Pharma Letter
Intas to acquire Coherus’ Udenyca assets for up to $558m - World Pharmaceutical Frontiers
Goodbye Biosimilars: Coherus Sells Udenyca To Intas For Half A Billion - News & Insights
S&P 500 Total Return (TCM23) Quote - The Globe and Mail
Intas Pharma to acquire Udenyca business from Coherus BioSciences - Medical Dialogues
Coherus Continues Funding IO Ambitions By Offloading Biosimilars - News & Insights
TSX Consumer Discretionary Capped Index (TTCD) QuotePress Release - The Globe and Mail
TSX Composite High Beta Index (TXHB) QuotePress Release - The Globe and Mail
Redwood City-based Coherus' stock surges after major drug sale - The Business Journals
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Raleigh pharmaceutical company expands portfolio with $558M deal - The Business Journals
Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M - BioPharma Dive
Coherus unloads Udenyca in $558M deal to power immuno-oncology ambitions - FirstWord Pharma
Coherus shares surge on $558M Udenyca divestiture deal By Investing.com - Investing.com South Africa
Coherus shares surge on $558M Udenyca divestiture deal - Investing.com
Unusually active option classes on open December 3rd - TipRanks
Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth - The Malaysian Reserve
Why Is Coherus BioSciences Stock Trading Higher On Tuesday? - Inkl
Coherus Biosciences agrees to divest UDENYCA franchise for up to $558M - TipRanks
Coherus Bio jumps on deal to divest biosimilar of Amgen's Neulasta - XM
Coherus BioSciences Shares Rise 22% on Divestiture Agreement With Intas Pharmaceuticals - MarketWatch
Coherus Biosciences Sells UDENYCA Franchise to Intas - TipRanks
Coherus BioSciences inks $558.4M deal with Intas Pharmaceuticals; shares rally - Investing.com
Coherus BioSciences to divest UDENYCA franchise for up to $558.4M (NASDAQ:CHRS) - Seeking Alpha
Coherus Biosciences to sharpen fcous on immuno-oncology portfolio - TipRanks
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. - GlobeNewswire
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas - The Bakersfield Californian
CHRS (Coherus BioSciences) 50-Day SMA : $0.92 (As of Nov. 30, 2024) - GuruFocus.com
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference - The Manila Times
Coherus BioSciences to Present at Citi Healthcare Conference's Oncology Panel | CHRS Stock News - StockTitan
Coherus BioSciences Inc (CHRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances - GuruFocus.com
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Coherus BioSciences, Inc. (NASDAQ:CHRS) Sees Significant Growth in Short Interest - MarketBeat
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):